Literature DB >> 10884371

Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis.

H Jakubowski1, L Zhang, A Bardeguez, A Aviv.   

Abstract

Editing of the nonprotein amino acid homocysteine by certain aminoacyl-tRNA synthetases results in the formation of the thioester homocysteine thiolactone. Here we show that in the presence of physiological concentrations of homocysteine, methionine, and folic acid, human umbilical vein endothelial cells efficiently convert homocysteine to thiolactone. The extent of this conversion is directly proportional to homocysteine concentration and inversely proportional to methionine concentration, suggesting involvement of methionyl-tRNA synthetase. Folic acid inhibits the synthesis of thiolactone by lowering homocysteine and increasing methionine concentrations in endothelial cells. We also show that the extent of post-translational protein homocysteinylation increases with increasing homocysteine levels but decreases with increasing folic acid and HDL levels in endothelial cell cultures. These data support a hypothesis that metabolic conversion of homocysteine to thiolactone and protein homocysteinylation by thiolactone may play a role in homocysteine-induced vascular damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884371     DOI: 10.1161/01.res.87.1.45

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  55 in total

1.  Aminoacyl-tRNA synthetases database.

Authors:  M Szymanski; M A Deniziak; J Barciszewski
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Metabolism and neurotoxicity of homocysteine thiolactone in mice: evidence for a protective role of paraoxonase 1.

Authors:  Kamila Borowczyk; Diana M Shih; Hieronim Jakubowski
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia.

Authors:  Brahmajee K Nallamothu; A Mark Fendrick; Gilbert S Omenn
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods.

Authors:  Subramanian Barathi; Muralidaran Charanya; Shivashanmugam Muthukumaran; Narayanasamy Angayarkanni; Vetrivel Umashankar
Journal:  J Ocul Biol Dis Infor       Date:  2011-02-09

5.  Investigation of the effect of homocysteinylation of substance P on its binding to the NK1 receptor using molecular dynamics simulation.

Authors:  Samira Davoudmanesh; Jafar Mohammadian Mosaabadi
Journal:  J Mol Model       Date:  2018-06-26       Impact factor: 1.810

6.  Association of MTHFR C677T polymorphism and risk of cerebrovascular disease in Chinese population: an updated meta-analysis.

Authors:  Ming-Jie Zhang; Jing-Cheng Li; Yan-Wei Yin; Bing-Hu Li; Yun Liu; Shao-Qiong Liao; Chang-Yue Gao; Li-Li Zhang
Journal:  J Neurol       Date:  2014-03-07       Impact factor: 4.849

Review 7.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

Review 8.  Hyperhomocysteinaemia and vascular injury: advances in mechanisms and drug targets.

Authors:  Yi Fu; Xian Wang; Wei Kong
Journal:  Br J Pharmacol       Date:  2017-09-22       Impact factor: 8.739

9.  Folate and one-carbon metabolism gene polymorphisms and their associations with oral facial clefts.

Authors:  Abee L Boyles; Allen J Wilcox; Jack A Taylor; Klaus Meyer; Ase Fredriksen; Per Magne Ueland; Christian A Drevon; Stein Emil Vollset; Rolv Terje Lie
Journal:  Am J Med Genet A       Date:  2008-02-15       Impact factor: 2.802

10.  Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization.

Authors:  Su Duy Nguyen; Dai-Eun Sok
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.